POLARISqb, a company specializing in quantum computing for drug discovery, has announced the launch of Quantum-Aided Drug Design (QuADD), a subscription-based SaaS platform. QuADD uses quantum computing to quickly identify top candidate molecules for drug targets, significantly speeding up drug discovery. The platform can build highly diverse and customized libraries of optimized molecules in just days, compared to the years and millions of dollars it takes using traditional wet lab testing methods. QuADD is the first quantum computing-based SaaS for drug discovery and is currently available for biotech and pharma companies.
Introduction
POLARISqb, a leader in quantum computing for drug discovery, has announced Quantum-Aided Drug Design (QuADD), a subscription-based platform that quickly identifies top candidate molecules for drug targets. Using quantum annealing computers, QuADD can build diverse and customized libraries of optimized molecules in days significantly faster than traditional wet lab testing. Founded in 2020 by Shahar Keinan and Bill Shipman, POLARISqb aims to revolutionize drug discovery processes with the speed of quantum computing.
POLARISqb Introduces Quantum-Aided Drug Design Platform
POLARISqb, a company specializing in accelerating drug discovery using quantum computing, has launched Quantum-Aided Drug Design (QuADD). QuADD is a subscription-based Software as a Service (SaaS) platform that quickly identifies a library of top candidate molecules for drug targets. Traditional library design involves wet lab testing that takes years, costs millions, and is limited to a narrow chemical space. With the power of quantum computing, QuADD can build highly diverse and customized libraries of optimized molecules in just days.
QuADD’s innovative approach translates the library building problem into an optimization problem that can be solved with a quantum annealing computer. Quantum annealing computers can complete optimization calculations much faster than conventional computers. This technology allows researchers to explore a much broader range of molecules for specific protein pockets and molecular properties, such as blood-brain barrier permeability, solubility, and toxicity. POLARISqb is the first company to offer a quantum computing-based SaaS for drug discovery.
QuADD’s Speed and Efficiency in Drug Discovery
QuADD can identify novel, bioavailable, and synthesizable lead-like hits from a library of 10^30 structures in just 1-3 days. The input for the QuADD pipeline is a customer-defined structure of the protein binding pocket and ligand. The result is a diverse, enriched library of candidate molecules that accelerate the start of the drug discovery pipeline.
Depending on the size of the protein binding pocket, QuADD identifies an optimized library of 1,000 to 10,000 molecules tailored to the customer’s specific protein pocket. This library is then ready for additional in-house computer-aided drug design (CADD) or wet lab testing. QuADD libraries contain molecules that have become commercially available, have favourable binding energy, drug-like functional groups, and correct binding orientations.
Availability and Security of the QuADD Platform
POLARISqb’s QuADD platform is available for drug discovery teams in biotech and pharma companies. Interested groups can contact POLARISqb for demonstrations and more information about how the technology could be employed in their own drug discovery pipelines. The QuADD platform is built to maintain strict confidentiality and is deployed in a secure isolated environment tailored to specific security and organizational requirements.
Polaris Quantum Biotech, founded in 2020 by Shahar Keinan and Bill Shipman, has created the first drug discovery platform built for quantum computing. The company uses the latest quantum and cloud computing, artificial intelligence, and machine learning to process, evaluate, and identify drug lead molecules much faster than alternative solutions. QuADD is available today and ready for biotech and pharmaceutical companies to revolutionize their drug discovery processes with the speed of quantum computing.
“With the power of quantum computing, QuADD is able to build highly diverse and customized libraries of optimized molecules in days,” said Shahar Keinan, CEO of POLARISqb.
Executive Summary
Polaris Quantum Biotech has developed Quantum-Aided Drug Design (QuADD), a subscription-based SaaS platform that uses quantum computing to identify top candidate molecules for drug targets rapidly. QuADD can build highly diverse and customized optimised molecule libraries in days, significantly accelerating the drug discovery process.
- POLARISqb, a leader in quantum computing for drug discovery, has announced Quantum-Aided Drug Design (QuADD), a subscription-based SaaS platform.
- QuADD quickly identifies top candidate molecules for drug targets, building highly diverse and customized libraries of optimized molecules in days.
- The platform uses quantum annealing computers, which can complete optimization calculations much faster than conventional computers.
- QuADD can find novel, bioavailable, and synthesizable lead-like hits from a library of 10^30 structures in 1-3 days.
- The input for the QuADD pipeline is a customer-defined structure of the protein binding pocket and ligand, resulting in a diverse, enriched library of candidate molecules.
- POLARISqb’s QuADD platform is currently available for drug discovery teams in biotech and pharma companies.
- Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, POLARISqb aims to revolutionize drug discovery processes with the speed of quantum computing.
Read More.